Diligence memo · auto-generated · as of July 2, 2026
Eutropics Pharmaceuticals, Inc.
Eutropics Pharmaceuticals, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Eutropics Pharmaceuticals, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Eutropics Pharmaceuticals, Inc. has raised $700K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $350K on 2021-11-03.
Most recent recorded round closed around 2024-01-11.
Valuation (modeled)modeled
Provath models Eutropics Pharmaceuticals, Inc. at approximately $2.1M (range $196K–$8.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.82× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (82% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 26 months.
Last raise 2.5 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 15% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 4% of those peers.
Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.